← Leaderboards
Latha Paka
Angion Biomedica Corporation
$8,163,089
Attributed
$8,163,089
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2006–14$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$8,163,089 · 10
By mechanism
R44$6,543,063 · 3
R43$1,620,026 · 7
Top collaborators
No co-investigators on record.
Most similar at Angion Biomedica Corporation
Same institution · by research overlap
- Prakash Narayan$20,015,268
- Weizhong Cai$17,018,171
- Youzhi Tong$426,946
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculeBaseMorbidity - Disease RateFibrosisMortality Vital StatisticsDoseTreatment EfficacyRouteSafetyDesignKidneyLungSmall Business Innovation Research GrantIn VitroHepatocyte Growth FactorIn VivoOralAnimal ModelPharmaceutical PreparationsPre-ClinicalCostClinical TrialsImmunosuppressive AgentsEtiology
Grant awards (14)
Anti-Fibrotic Therapy for Scleroderma/SSc$1,584,102
R44 · FY2014 · AR · contact PI
A Therapeutic for Radiation Induced Lung Injury$299,948
R43 · FY2014 · AI · contact PI
A Novel Small Molecule Therapeutic for Alcoholic Chronic Pancreatitis$224,347
R43 · FY2014 · AA · contact PI
Anti-Fibrotic Therapy for Scleroderma/SSc$619,112
R44 · FY2013 · AR · contact PI
Anti-Fibrotic Therapy for Scleroderma/SSc$606,272
R44 · FY2012 · AR · contact PI
Anti-Fibrotic Therapy for Scleroderma/SSc$287,606
R43 · FY2010 · AR · contact PI
Therapeutic Potential of PARP inhibitor for Acute Pancreatitis$219,145
R43 · FY2010 · DK · contact PI
Anti-Fibrotic Therapy for Pulmonary Fibrosis$900,595
R44 · FY2007 · HL · contact PI
Small Molecule Anti-Fibrotic Therapy for Scleroderma$215,956
R43 · FY2007 · AR · contact PI
Anti-Fibrotic Therapy for Pulmonary Fibrosis$973,815
R44 · FY2006 · HL · contact PI
Therapeutic Potential of Refanalin in Pulmonary Fibrosis$175,272
R43 · FY2004 · HL
SF/HGF Gene Transfer for Peripheral Ischemia$799,317
R44 · FY2003 · HL
Protection from Atherosclerosis by c-Met Agonist$197,752
R43 · FY2003 · HL
SF/HGF Gene Transfer for Peripheral Ischemia$1,059,850
R44 · FY2002 · HL